BioSpace News Archive

Array BioPharma will report financial results for the first quarter of fiscal 2018 and hold a conference call to discuss those results on Tuesday, October 31, 2017.

The Michael J. Fox Foundation for Parkinson’s Research and the Tau Consortium today announce a funding partnership to accelerate development of novel PET imaging tracers for the detection of the alpha-synuclein and tau proteins in the living brain.

The randomized, double blind, phase III, trial investigates the utility of Grafalon in reducing moderate to severe chronic graft-versus-host-disease.

Abaxis today reported financial results for the second fiscal quarter ended September 30, 2017.

NuVasive today announced that its Board of Directors approved a share repurchase program authorizing the purchase of up to $100M of the Company’s common stock over a three-year period commencing October 25, 2017.

NuVasive announced today financial results for the quarter ended September 30, 2017.

Amgen today announced the appointment of Wanda M. Austin to its Board of Directors, effective upon the December Board and committee meetings.

Medivir AB today announced that the FDA has granted Fast Track designation for the company´s product candidate MIV-711, for the treatment of osteoarthritis (OA).

BioAmber announced today that it has accepted the resignation of Mr. Fabrice Orecchioni as President and COO.

DECLARES 85TH CONSECUTIVE QUARTERLY DIVIDEND [24-October-2017] ACTON, Mass., Oct. 24, 2017 /PRNewswire/ -- Psychemedics Corporation (NASDAQ: PMD) today announced third quarter financial results for the period ended September 30, 2017. The Company also announced a quarterly dividend of $0.15 per share payable to shareholders of record as of November 6, 2017,